Obesity is a significant public health concern and a growing epidemic in the G7 countries. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Compounding this problem is that available treatments do not have desirable risk:benefit profiles at low prices; in addition, few novel agents are in development for obesity. Consequently, there is a huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. However, given the prevalence of obesity, even if such an agent were developed and approved, payer-controlled access would likely be necessary to limit the impact on limited healthcare budgets.

Questions answered:

  • Which metabolic and central pathways have high potential as drug targets?
  • What is the prevalence of obesity in the major pharmaceutical markets under study?
  • How is obesity currently treated? What do experts think about Novo Nordisk’s Saxenda as a treatment for obese / overweight patients?
  • What is the current level of unmet need according to obesity experts? How will this need be addressed over the 2018-2028 forecast period?
  • What is the commercial potential of Novo Noridsk’s semaglutide and Eli Lilly’s tirzepatide? How do leaders in the field of obesity management rate these drug candidates?
  • How will the obesity market evolve over the next ten years?

Product description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Updates
      • November 2019
        • November 2019
      • September 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Obesity / Overweight?
        • What Factors Are Constraining the Market for Obesity / Overweight?
      • Drug-Class-Specific Trends
        • GLP-1 Receptor Agonists
        • Dual GIP / GLP-1 Receptor Agonists
        • Fixed-Dose Combinations
        • Serotonin Receptor Agonists
        • Lipase Inhibitors
        • Noradrenergic Anorectic Agents
        • Off-Label Prescription Drugs
    • Forecast
      • Market Forecast Assumptions - Obesity (2018-2028) - November 2019
      • Market Forecast Dashboard - Obesity (2018-2028) - November 2019
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
      • Natural History
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalence of Obesity and Overweight
        • Obesity Subtypes by Disease Severity
        • Drug-Eligible Overweight Cases
        • Diagnosed Prevalent Cases of Obesity and Overweight
        • Drug-Treated Prevalent Cases of Obesity and Overweight
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • GLP-1 Receptor Agonists
        • Fixed-Dose Combinations
        • Serotonin Receptor Agonists
        • Lipase Inhibitors
        • Noradrenergic Anorectic Agents
        • Off-Label Prescription Drugs
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Obesity / Overweight
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • GLP-1 Receptor Agonists
        • Dual GIP / GLP-1 Receptor Agonists
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Obesity / Overweight
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Obesity Bibliography

Author(s): Rameshwar Prajapati, Ph.D., M.S. (Pharm.); Joseph Granato, MPH

Rameshwar Prajapati, (Pharm.), is a business insights analyst in Decision Resources Group’s cardiovascular, metabolic, renal, and hematologic disorders team, focusing primarily on obesity. In this role, his main function is to perform primary and secondary research related to obesity and its treatment, as well as providing insights and assessments for the major pharmaceutical markets regarding weight loss medications. Rameshwar holds a bachelor’s degree in pharmacy from Dr. Gour University, Sagar, India. He obtained his master’s and doctorate degree in pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Nagar, India. Rameshwar also received a German Academic Exchange Service (DAAD) fellowship to conduct his research on P-glycoprotein at the University of Bonn, Germany.

Joseph Granato joined Decision Resources Group in 2012 and previously worked on both Market Access and Global Market Access ; Joseph is currently responsible for forecasting the prevalence and incidence of disease populations throughout the ; He is also tasked with identifying at risk populations and developing new epidemiological methods used to predict overall population health. He received his from Des Moines University where he worked on several population health projects including the delivery of continuing medical education on tick-borne ; He also holds a in Animal Science from the University of ; Prior to his time with DRG Joseph worked with the Monroe County Health Department on the surveillance of reportable diseases including Dengue Fever.

Related Reports

Obesity/Overweight | Unmet Need | US/EU | 2019

Obesity is arguably the most pressing public health issue in the United States with its chronic progression that is associated with both type 2 diabetes and adverse cardiovascular health. Current t...

View Details

Obesity/Overweight | Unmet Need | Detailed, Expanded Analysis (US/EU)

Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Following a seri...

View Details

Obesity/Overweight | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of obesity/overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report diagnosed prevalence of obesity/...

View Details